Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ME2 | P23368 | 6/20 | 0.43 |
| ▸ | ME1 | P48163 | 6/20 | 0.43 |
| ▸ | ME3 | Q16798 | 6/20 | 0.43 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.35 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | SLC27A1 | Q6PCB7 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5714403 | 0.91 | PANK3 (0.42) | ME2ME1ME3PANK3HRH3 | |
| SCHEMBL5714722 | 0.90 | PANK3 (0.42) | ME2ME1ME3PANK3HRH3 | |
| SCHEMBL5715038 | 0.90 | ME2 (0.43) | ME2ME1ME3PANK3GPR119 | |
| SCHEMBL5715018 | 0.89 | SMN1; SMN2 (0.52) | HPGDSMN1; SMN2 | |
| SCHEMBL5714975 | 0.89 | HRH3 (0.40) | ME2ME1ME3PANK3HRH3 | |
| SCHEMBL5904372 | 0.89 | PANK3 (0.40) | ME2ME1ME3PANK3GPR119 | |
| SCHEMBL5714943 | 0.86 | HSD17B10 (0.49) | HPGDSMN1; SMN2 | |
| SCHEMBL5714729 | 0.86 | ME2 (0.46) | ME2ME1ME3PANK3HRH3 | |
| SCHEMBL5715233 | 0.84 | ME2 (0.45) | ME2ME1ME3PANK3HRH3 | |
| SCHEMBL5715416 | 0.82 | ME2 (0.43) | ME2ME1ME3PANK3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160819-A1 | Substitued piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | claimed |
| EP-1636189-A1 | 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004111007-A1 | 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160819-A1 | Substitued piperazine carbamates | LIPE, PNLIP, LIPC | ME2 854/4885ME1 2914/4885ME3 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.